Navigation Links
ThromboGenics Announces 2007 Full Year Results
Date:3/13/2008

LEUVEN, Belgium, March 13 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular diseases, today announces a business update and its financial results for the twelve month period ending 31 December 2007. During this period, ThromboGenics has raised additional funds to invest in its development pipeline and has continued to make good progress with its clinical programs.

Highlights

- Successful placing of a total of 5,166,517 shares in May 2007, which increased the Company's free float to 70%, and led to an improvement in stock liquidity. As part of this placement, ThromboGenics issued 2,214,030 new shares raising a total of EUR23.9m. These new funds have strengthened ThromboGenics financial position, and have allowed it to continue to advance its product pipeline and strengthen its operations. The Company's cash position amounted to EUR46.1m as of 31 December 2007.

- Achievement of key milestones with microplasmin for ophthalmic indications. Initiation of a Phase IIb clinical trial of microplasmin in vitrectomy (MIVI III - Microplasmin for Vitreous Injection) in the United States, as well as the initiation of two Phase IIa clinical trials of microplasmin in Europe, for vitreomacular traction and diabetic macular edema (MIVI IIT and MIVI II, respectively). Positive results from the Phase I MIVI I and the MIVI IIT were presented at two international ophthalmology conferences.

- Positive Phase I results with TB-402 (anti-factor VIII), in collaboration with BioInvent International. TB-402 is being developed as a long acting anti-coagulant for the treatment and prevention of deep vein thrombosis (DVT) and atrial fibrillation. The product will enter Phase II clinical studies by the end of 2008.

- Exciting pre-clinical results with TB-403 (anti-PIGF) were published in Cell as the featured article in the November 2, 2007 issue. The paper highlighted that antibodies against PIG
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
2. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
3. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
6. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
7. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
8. EntreMed Announces 2008 Corporate and Clinical Program Priorities
9. Arpida Announces Full Year 2007 Financial Results
10. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
11. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... NEW YORK , Sept. 16, 2014 This ... by the following Product Segments: Software, Hardware, and Biocontent. The ... Canada , Japan , ... Latin America , and Rest of World. Annual estimates ... Also, a seven-year historic analysis is provided for these markets. ...
(Date:9/16/2014)... From cell phones to cars and flashlights, ... Scientists and technology companies constantly are seeking ways ... the first time using a water-based solution, researchers ... long-lasting and more efficient nuclear battery that could ... reliable energy source in automobiles and also in ...
(Date:9/16/2014)... 2014  Donald Fresne, President and CEO of Egenix, Inc. ... , PhD to its Scientific Advisory Committee. Dr. ... France , performed research at Embl (European Molecular Biology ... the French institute of health and medical research. He is ... Curie Institute, Orsay, France , and at ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 ... initiatives to position themselves for their 89th ... labeling and encoding, Pharma Packaging Solutions is ... hardware and software and new procedures. Establishing ... Good Manufacturing Practices (cGMP), Pharma Packaging Solutions ...
Breaking Biology Technology:Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2Adding Serialization Capabilities and Expanded Capacity, Pharma Packaging Solutions Is Preparing for 89th Year of Business 2
... 2, 2011 Forensic DNA profiling has become a ... the aftermath of mass violence and disaster, but until ... and analyze the major ethical and policy challenges associated ... (Logo: http://photos.prnewswire.com/prnh/20020422/CMULOGO) The National Institutes of ...
... biotech industry opened the New Year quietly with the Burrill ... Meanwhile, the capital markets recorded their strongest January in years. ... 2.7 percent gain and the Nasdaq Composite index closed up ... biotech,s performance on the capital markets, the mood at the ...
... 2011 Sigma Life Science, the innovative biological products and ... announced that its SAGE Labs initiative has partnered with Cofactor ... the most widely used strains of rat.  As part of ... data using next generation sequencing systems, while SAGE Labs plans ...
Cached Biology Technology:CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 2CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 3CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 4Biotech Begins Year on a Quiet, but Optimistic Note 2Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database 2Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database 3Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database 4
(Date:9/16/2014)... morbidity amongst women in Australia is increased by ... today (17 September) in BJOG: An International ... generally enjoy high standards of living; however, existing ... particular between indigenous and non indigenous Australians. , ... impact of socioeconomic position on severe maternal morbidities ...
(Date:9/16/2014)... than $100 trillion in cumulative public and private ... (CO2)a 40 percent reduction of urban passenger transport ... expands public transportation, walking and cycling in cities, ... University of California, Davis, and the Institute for ... an estimated 1.4 million early deaths could be ...
(Date:9/16/2014)... September 13, 2014. The fire is human-caused and ... acres in size and is mostly being fueled by ... Monday night due to higher humidity. Yesterday (8/15), ... to construct a fireline on the West and North sides ... the fire: , 7 20-person Crews, 4 Hot Shot Crews, ...
Breaking Biology News(10 mins):New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5
... interested in ancient life have a wealth of fossils and ... far back as 540 million years ago ?when animals with ... complex life older than 540 million years is scant and ... Tech in the United States and Nanjing Institute of Geology ...
... persist for days and even weeks on environmental ... computer keyboard covers and acrylic fingernails, according to ... of the American Society for Microbiology. , Methicillin-resistant ... hospital-acquired infections in the United States. Staphylococcal infections ...
... Pittsburgh researchers first to report function of tunneling nanotubules ... by an extensive network of tiny tunnels that, like ... shoot signals to distant cells. This surprising discovery, being ... researchers in the September issue of the journal Immunity, ...
Cached Biology News:Virginia Tech, Nanjing Institute researchers discover half-billion year-old fossils 2Virginia Tech, Nanjing Institute researchers discover half-billion year-old fossils 3'Underground' tunnels discovered as means for communication between immune system cells 2'Underground' tunnels discovered as means for communication between immune system cells 3'Underground' tunnels discovered as means for communication between immune system cells 4
... to Ki67 - Proliferation Marker, prediluted ... related nuclear protein, expressed by proliferating cells ... cycle (G1, S, G2 and M phase). ... Ki67 antibodies are useful in establishing the ...
... g of monoclonal antibody reactive against the complex ... are highest in growing cultured cells. SURF1 is ... which is thought to participate in the folding ... this subunit. Mutations of SURF1, particularly ones that ...
Phenytoin-BSA Isolated IgY DFc Drug...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
Biology Products: